Highlights of Q4 & FY24:
- FY24:
- Increasing demand translating into revenue growth in the latter part of the year.
- Stelis Biopharma
- The repurposing of acquired facility expected to complete in the second half of 2024
- The facility will offer production of both drug substance and drug product
- Continue to invest in
- SynVent - covering a range of therapeutic areas including oncology, gene therapy, central nervous system (CNS) and pain management for use in human and animal health
- Syn.AI - expanded to enable it to identify the most effective drug targets for combating disease by enhancing its target identification and validation packages
- Sibaji Biswas promoted from CFO to Chief Financial Officer and Executive Director
- Expect FY25
- Sales growth of high single digits to low double digits
- EBITDA margin to be similar
- PAT growth in single digits
- Q4FY24:
- A new capability for purifying and separating chiral compounds and HPAPIs (Highly Potent Active Pharmaceutical Ingredients) used for cancer
- Q4 Performance was lower than expected due to reduced demand for R&D services within US biotech stemming from a difficult funding environment, and is recovering
Subscribe To Our Free Newsletter |